The FDA approved Eli Lilly's Zepbound as the first drug for obesity-linked moderate-to-severe sleep apnea, potentially transforming treatment options for 80 million Americans.

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

New research reveals how sleep apnea may accelerate brain aging and cognitive decline, with experts sharing crucial insights ...

The FDA has granted approval for its first medication for certain patients with sleep apnea—the weight-loss drug Zepbound.

Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The new approval means that insurance providers will likely cover the medication for people with sleep apnea and obesity.

The Food and Drug Administration on Friday approved Eli Lilly’s anti-obesity drug Zepbound as the first prescription medicine ...

The Food and Drug Administration (FDA) approved a weight-loss drug to help sleep apnea, becoming the first drug to treat the disorder affecting millions of Americans. On Friday, the federal agency ...

Nocturnal enuresis is more common in children with obstructive sleep apnea (OSA), according to a study published online Sept. 23 in Children. In a new analysis of national data, researchers at the ...

Obstructive sleep apnea (OSA) and the metabolic syndrome have a strong association with each other owing to their common feature of obesity, but an association independent of obesity has been ...

“It means everything, especially being back in my hometown, giving back to the community and the children that could be the next me" Our Town West Branch invites anyone to experience its ...